JITC

Human CD19-specific switchable CAR T-cells are efficacious as constitutively active CAR T-cells but cause less morbidity in a mouse model of human CD19⁺ malignancy
Christopher A Pennell, Heather Campbell, Meghan D Storlie, Sara Bolivar-Wagers, Mark J Osborn, Yosef Refaeli, Michael Jensen, Sophie Viaud, Travis S Young, Bruce R Blazar

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005934; DOI: 10.1136/jitc-2022-005934
Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies
Joshua T Kowalczyk, Kellsye P Fabian, Michelle R Padget, Diana C Lopez, Austin TK Hoke, Clint T Allen, Mario Hermsen, Nyall R London,, James W Hodge

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005752; DOI: 10.1136/jitc-2022-005752
Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
Olivier Michielin, Aly-Khan Lalani, Caroline Robert, Padmanee Sharma, Solange Peters

Journal for ImmunoTherapy of Cancer Jan 2022, 10 (1) e003024; DOI: 10.1136/jitc-2021-003024
Development of ⁸⁹Zr-anti-CD103 PET imaging for non-invasive assessment of cancer reactive T cell infiltration
Arjan Kol, Xiaoyu Fan, Marta A. Wazynska, Sander M.J. van Duijnhoven, Danique Giesen, Annechien Plat, Hans Van Eenennaam, Philip H. Elsinga, Hans W. Nijman, Marco de Bruyn

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e004877; DOI: 10.1136/jitc-2022-004877
Serum albumin: a pharmacokinetic marker for optimizing treatment outcome of immune checkpoint blockade
Ming Zheng

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005670; DOI: 10.1136/jitc-2022-005670
Efficient preclinical treatment of cortical T cell acute lymphoblastic leukemia with T lymphocytes secreting anti-CD1a T cell engagers
Anaïs Jiménez-Reinoso, Néstor Tirado, Alba Martinez-Moreno, Víctor M Díaz, Marina García-Peydró, Oana Hangiu, Laura Díez-Alonso, Ángela Albitre, Petronila Penela, Maria L Toribio, Pablo Menéndez, Luis Álvarez-Vallina, Diego Sánchez Martínez

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005333; DOI: 10.1136/jitc-2022-005333
Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial
Xiao Han, Xiaoyong Tang, Hui Zhu, Dongyuan Zhu, Xiqin Zhang, Xiangjiao Meng, Ying Hua, Zhongtang Wang, Yan Zhang, Wei Huang, Linlin Wang, Shuanghu Yuan, Pinliang Zhang, Heyi Gong, Yulan Sun, Yingjie Zhang, Zengjun Liu, Xiaomeng Dong, Fei Gai, Zhan Huang, Changbin Zhu, Jun Guo, Zhehai Wang

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e004952; DOI: 10.1136/jitc-2022-004952
Systemic cellular viroimmunotherapy for canine high-grade gliomas
Ana Cloquell, Isidro Mateo, Stefano Gambera, Martí Pumarola, Ramon Alemany, Javier García-Castro, Ana Judith Perisé-Barrios

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005669; DOI: 10.1136/jitc-2022-005669
Liquid biopsies, are we ready for prime time?
Nicola Normanno, Kathi Apostolidis, Mark Stewart

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006302; DOI: 10.1136/jitc-2022-006302
MUC1-C is a master regulator of MICA/B NKG2D ligand and exosome secretion in human cancer cells
Yoshihiro Morimoto, Nami Yamashita, Tatsuaki Daimon, Haruka Hirose, Shizuka Yamano, Naoki Haratake, Satoshi Ishikawa, Atrayee Bhattacharya, Atsushi Fushimi, Rehan Ahmad, Hidekazu Takahashi, Olga Dashevsky, Constantine Mitsiades, Donald Kufe

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006238; DOI: 10.1136/jitc-2022-006238

Main menu

JITC

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

JITC

Pages